BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Denosumab (Prolia) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Denosumab (Prolia)\, from ClinicalTrials.
 gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06332014-3268@assetmemo.bio
DTSTAMP:20261121T005733Z
DTSTART;VALUE=DATE:20270123
DTEND;VALUE=DATE:20270124
SUMMARY:Denosumab (Prolia): Phase 4 readout est. (NCT06332014)
DESCRIPTION:Denosumab (Prolia)\, phase 4\, Osteoporosis.\nStudy: Evaluation
  of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Main
 land China\nEstimated primary completion: 23 January 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/denosumab-prolia#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06332014
URL:https://assetmemo.bio/drug/denosumab-prolia#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04608630-3268@assetmemo.bio
DTSTAMP:20261121T005733Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Denosumab (Prolia): Phase 2 readout est. (NCT04608630)
DESCRIPTION:Denosumab (Prolia)\, phase 2\, Osteoporosis.\nStudy: Bone Loss 
 Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults\nEst
 imated primary completion: 28 February 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/denosumab-prolia#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT04608630
URL:https://assetmemo.bio/drug/denosumab-prolia#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04800367-3268@assetmemo.bio
DTSTAMP:20261121T005733Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Denosumab (Prolia): Phase 2 readout est. (NCT04800367)
DESCRIPTION:Denosumab (Prolia)\, phase 2\, Osteoporosis.\nStudy: Romosozuma
 b/Denosumab Study for Premenopausal IOP\nEstimated primary completion: Mar
 ch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/denosumab-pr
 olia#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T04800367
URL:https://assetmemo.bio/drug/denosumab-prolia#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07271771-3268@assetmemo.bio
DTSTAMP:20261121T005733Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Denosumab (Prolia): Phase 4 readout est. (NCT07271771)
DESCRIPTION:Denosumab (Prolia)\, phase 4\, Osteoporosis.\nStudy: The Effect
  of Denosumab on Muscle and Strength and Insulin Sensitivity\nEstimated pr
 imary completion: 1 March 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/denosumab-prolia#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07271771
URL:https://assetmemo.bio/drug/denosumab-prolia#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06643780-3268@assetmemo.bio
DTSTAMP:20261121T005733Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Denosumab (Prolia): Phase 4 readout est. (NCT06643780)
DESCRIPTION:Denosumab (Prolia)\, phase 4\, Osteoporosis.\nStudy: RANK-ligan
 d Inhibition to Combat Sarcopenia With Underlying Osteoporosis\nEstimated 
 primary completion: April 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/denosumab-prolia#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06643780
URL:https://assetmemo.bio/drug/denosumab-prolia#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06588153-3268@assetmemo.bio
DTSTAMP:20261121T005733Z
DTSTART;VALUE=DATE:20270427
DTEND;VALUE=DATE:20270428
SUMMARY:Denosumab (Prolia): Phase 4 readout est. (NCT06588153)
DESCRIPTION:Denosumab (Prolia)\, phase 4\, Osteoporosis.\nStudy: A Study fo
 r the Evaluation of Efficacy and Safety of Prolia® in Participants With G
 lucocorticoid-induced Osteoporosis in Mainland China\nEstimated primary co
 mpletion: 27 April 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/denosumab-prolia#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06588153
URL:https://assetmemo.bio/drug/denosumab-prolia#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03921060-3268@assetmemo.bio
DTSTAMP:20261121T005733Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Denosumab (Prolia): Phase 4 readout est. (NCT03921060)
DESCRIPTION:Denosumab (Prolia)\, phase 4\, Osteoporosis.\nStudy: Markers of
  Osteoporosis in Cystic Fibrosis\nEstimated primary completion: July 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/denosumab-prolia#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0392106
 0
URL:https://assetmemo.bio/drug/denosumab-prolia#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07063797-3268@assetmemo.bio
DTSTAMP:20261121T005733Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Denosumab (Prolia): Phase na readout est. (NCT07063797)
DESCRIPTION:Denosumab (Prolia)\, phase na\, Osteoporosis.\nStudy: Study on 
 the Intervention Effect of Denosumab on High-Risk Patients With Osteoporot
 ic Fractures in Type 2 Diabetes\nEstimated primary completion: 31 July 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/denosumab-prolia#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07063
 797
URL:https://assetmemo.bio/drug/denosumab-prolia#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07757373-3268@assetmemo.bio
DTSTAMP:20261121T005733Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Denosumab (Prolia): Phase 4 readout est. (NCT07757373)
DESCRIPTION:Denosumab (Prolia)\, phase 4\, Osteoporosis.\nStudy: Romosozuma
 b Versus Denosumab In Glucocorticoid-induced Osteoporosis: An Extended Obs
 ervation Of a Clinical Trial at 6 Years\nEstimated primary completion: 30 
 September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/denos
 umab-prolia#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07757373
URL:https://assetmemo.bio/drug/denosumab-prolia#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05010590-3268@assetmemo.bio
DTSTAMP:20261121T005733Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Denosumab (Prolia): Phase 4 readout est. (NCT05010590)
DESCRIPTION:Denosumab (Prolia)\, phase 4\, Osteoporosis.\nStudy: Anabolic T
 herapy in Postmenopausal Osteoporosis\nEstimated primary completion: 1 Oct
 ober 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/denosumab-
 prolia#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05010590
URL:https://assetmemo.bio/drug/denosumab-prolia#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06524960-3268@assetmemo.bio
DTSTAMP:20261121T005733Z
DTSTART;VALUE=DATE:20271011
DTEND;VALUE=DATE:20271012
SUMMARY:Denosumab (Prolia): Phase 1/2 readout est. (NCT06524960)
DESCRIPTION:Denosumab (Prolia)\, phase 1/2.\nStudy: Denosumab for Type 1 Di
 abetes\nEstimated primary completion: 11 October 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/denosumab-prolia#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06524960
URL:https://assetmemo.bio/drug/denosumab-prolia#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07056478-3268@assetmemo.bio
DTSTAMP:20261121T005733Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Denosumab (Prolia): Phase 3 readout est. (NCT07056478)
DESCRIPTION:Denosumab (Prolia)\, phase 3.\nStudy: RANKL Inhibition to Comba
 t Sarcopenia in Hip Fracture Patients\nEstimated primary completion: 1 Jan
 uary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/denosumab-
 prolia#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07056478
URL:https://assetmemo.bio/drug/denosumab-prolia#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07546552-3268@assetmemo.bio
DTSTAMP:20261121T005733Z
DTSTART;VALUE=DATE:20280315
DTEND;VALUE=DATE:20280316
SUMMARY:Denosumab (Prolia): Phase na readout est. (NCT07546552)
DESCRIPTION:Denosumab (Prolia)\, phase na\, Osteoporosis.\nStudy: Clinical 
 Relevance of Modifying RANKL Signaling During Folliculogenesis\nEstimated 
 primary completion: 15 March 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/denosumab-prolia#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07546552
URL:https://assetmemo.bio/drug/denosumab-prolia#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07281586-3268@assetmemo.bio
DTSTAMP:20261121T005733Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Denosumab (Prolia): Phase 4 readout est. (NCT07281586)
DESCRIPTION:Denosumab (Prolia)\, phase 4\, Osteoporosis.\nStudy: Step-down 
 Therapy After Long-term Osteoporosis Treatment\nEstimated primary completi
 on: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /denosumab-prolia#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07281586
URL:https://assetmemo.bio/drug/denosumab-prolia#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06118905-3268@assetmemo.bio
DTSTAMP:20261121T005733Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Denosumab (Prolia): Phase 4 readout est. (NCT06118905)
DESCRIPTION:Denosumab (Prolia)\, phase 4\, Osteoporosis.\nStudy: Preserving
  Geriatric Muscle With an Osteoporosis Medication\nEstimated primary compl
 etion: 28 February 2029. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/denosumab-prolia#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06118905
URL:https://assetmemo.bio/drug/denosumab-prolia#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06938152-3268@assetmemo.bio
DTSTAMP:20261121T005733Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Denosumab (Prolia): Phase 4 readout est. (NCT06938152)
DESCRIPTION:Denosumab (Prolia)\, phase 4\, Osteoporosis.\nStudy: Effects of
  Cycle Therapy vs Sequential Therapy With Romosozumab and Denosumab in Pos
 tmenopausal Osteoporosis Patients\nEstimated primary completion: 30 April 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/denosumab-proli
 a#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 938152
URL:https://assetmemo.bio/drug/denosumab-prolia#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07772609-3268@assetmemo.bio
DTSTAMP:20261121T005733Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Denosumab (Prolia): Phase 4 readout est. (NCT07772609)
DESCRIPTION:Denosumab (Prolia)\, phase 4\, Osteoporosis.\nStudy: Sequential
  Treatment With Romosozumab Followed by Denosumab vs. Zoledronic Acid for 
 Gains in HIP BMD\nEstimated primary completion: 31 December 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/denosumab-prolia#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07772609
URL:https://assetmemo.bio/drug/denosumab-prolia#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04547348-3268@assetmemo.bio
DTSTAMP:20261121T005733Z
DTSTART;VALUE=DATE:20300801
DTEND;VALUE=DATE:20300802
SUMMARY:Denosumab (Prolia): Phase 3 readout est. (NCT04547348)
DESCRIPTION:Denosumab (Prolia)\, phase 3.\nStudy: The DENOCHARCOT Trial\nEs
 timated primary completion: 1 August 2030. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/denosumab-prolia#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT04547348
URL:https://assetmemo.bio/drug/denosumab-prolia#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06767150-3268@assetmemo.bio
DTSTAMP:20261121T005733Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Denosumab (Prolia): Phase 4 readout est. (NCT06767150)
DESCRIPTION:Denosumab (Prolia)\, phase 4\, Osteoporosis.\nStudy: StrAtegies
  For Zoledronic Acid Post-dEnosumab Discontinuation in Postmenopausal oSTe
 oporosis\nEstimated primary completion: October 2030. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/denosumab-prolia#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06767150
URL:https://assetmemo.bio/drug/denosumab-prolia#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07909304-3268@assetmemo.bio
DTSTAMP:20261121T005733Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Denosumab (Prolia): Phase 4 readout est. (NCT07909304)
DESCRIPTION:Denosumab (Prolia)\, phase 4\, Osteoporosis.\nStudy: Romosozuma
 b and Denosumab Combination Therapy for Osteoporosis\nEstimated primary co
 mpletion: December 2030. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/denosumab-prolia#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07909304
URL:https://assetmemo.bio/drug/denosumab-prolia#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
